Tool
GLP-1 Transition Planner
Four questions. In return you get the options that apply to you, each with what it actually costs, what its terms hide, and the question to take to a prescriber. It will not tell you which to pick — that isn't a decision a web page should make for you, and we have no stake in the answer. Nothing you tap is stored or sent anywhere; this runs entirely in your browser.
1. What were you on?
2. What prescription coverage do you have?
3. How much supply do you have left?
4. Injection or pill?
Prices verified September 25, 2026 from each manufacturer's own published terms. They change without notice. This tool is educational, is not medical advice, and is not a referral to any pharmacy, platform or clinic. The full explanation of what changed and why lives on the GLP-1 transition hub.
How the planner chooses what to show
The planner asks four things: what you were taking, what prescription coverage you have, how much supply is left, and whether you would rather inject or take a pill. Each answer removes options that cannot apply. A commercial plan that covers obesity medicine brings up the insurance route and its prior-authorisation questions; no coverage brings up the manufacturers' cash programmes; Medicare or Medicaid removes the manufacturer savings cards, which exclude government beneficiaries; a preference for a pill brings the oral medicines forward. Supply matters because a gap changes both the price and the dose you restart at.
| Coverage answer | Options the planner shows |
|---|---|
| Commercial plan that covers obesity medicine | Branded GLP-1 on your insurance, Branded GLP-1, cash-pay direct from the manufacturer, An oral GLP-1, Compounded GLP-1 through a 503A pharmacy, Liraglutide, Stopping |
| Commercial plan that does not | Branded GLP-1, cash-pay direct from the manufacturer, An oral GLP-1, Compounded GLP-1 through a 503A pharmacy, Liraglutide, Stopping |
| Medicare Part D | The Medicare GLP-1 Bridge, An oral GLP-1, Compounded GLP-1 through a 503A pharmacy, Liraglutide, Stopping |
| Medicaid | Medicaid, An oral GLP-1, Compounded GLP-1 through a 503A pharmacy, Liraglutide, Stopping |
| None, paying cash | Branded GLP-1, cash-pay direct from the manufacturer, An oral GLP-1, Compounded GLP-1 through a 503A pharmacy, Liraglutide, Stopping |
For each option the planner shows what it costs, what the headline hides and the question to take to a prescriber. It does not rank the options or recommend one, and nothing you tap is stored or sent anywhere.
Where the prices come from
Every price is the manufacturer's own published figure, read from its terms on September 25, 2026: Lilly's LillyDirect self-pay terms for Zepbound and Foundayo, and Novo Nordisk's NovoCare terms for Wegovy.1,2 They are dated on the page because they change without notice, and the conditions matter as much as the numbers: Zepbound's lower self-pay price, for example, depends on each refill being completed within 45 days of the last delivery.1 The planner names no pharmacy, telehealth platform or clinic. It describes compounding through a 503A pharmacy as an option in general terms, with what the rules now allow, because recommending a seller is the one thing this site does not do.
What the labels say about gaps and switching
A transition usually means a gap, and the labels are specific about what a gap does. Semaglutide has a half-life of about a week and remains in the circulation for about five weeks after the last dose, so a short gap does not return you to zero straight away.3 But restarting at a high dose after a longer gap is what the labels warn against: Wegovy's says that after two or more consecutive missed doses, escalation should restart at a lower dose to reduce gastrointestinal side effects,4 and Zepbound's allows a missed dose to be taken only within 4 days.5 Moving between Wegovy forms has its own rule: someone on the 2.4 mg injection can switch to 25 mg tablets one week after the last injection.4
A compounded dose is not automatically the same as a branded dose with the same number. Compounded products are dosed from vials, often in syringe units, and the concentration decides what a unit contains; the step to start on with a branded product is a prescriber's decision, made with the gap and your tolerance in mind. The titration planner lays out each label's escalation steps, and the reconstitution calculator converts units to milligrams.
What the planner will not do
It will not tell you which option to pick, estimate what your plan will approve, convert a compounded dose into a branded one, or point you to anywhere that sells either. For why compounded GLP-1s were available and what changed, what the 503A and 503B rules now allow, and what the trials found about stopping, see the GLP-1 transition hub.
Sources
- Eli Lilly and Company. LillyDirect Self Pay Journey Program terms for Zepbound, and Foundayo coverage and savings terms, as published on lilly.com; read September 25, 2026.
- Novo Nordisk. NovoCare Pharmacy self-pay terms for Wegovy injection and tablets, as published on novocare.com; read September 25, 2026.
- Novo Nordisk. OZEMPIC (semaglutide) injection, US prescribing information, section 12.3: elimination half-life approximately 1 week; semaglutide will be present in the circulation for about 5 weeks after the last dose. DailyMed version of June 10, 2026, read September 30, 2026.
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, US prescribing information: if 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage; switching from WEGOVY 2.4 mg injection to 25 mg tablets one week after discontinuing the injection. DailyMed version of June 30, 2026, read September 30, 2026.
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, US prescribing information: administer a missed dose within 4 days (96 hours); otherwise skip it. DailyMed version of September 2, 2026, read September 30, 2026.
This explainer describes how the tool works and what its numbers rest on. It is not medical advice and does not recommend any dose or product.